Cytophage Technologies (TSXV:CYTO) Scaled Net Operating Assets : 0.49 (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Cytophage Technologies Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cytophage Technologies's operating assets for the quarter that ended in Mar. 2024 was C$3.18 Mil. Cytophage Technologies's operating liabilities for the quarter that ended in Mar. 2024 was C$0.53 Mil. Cytophage Technologies's Total Assets for the quarter that ended in Dec. 2023 was C$5.46 Mil. Therefore, Cytophage Technologies's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.49.

Cytophage Technologies Scaled Net Operating Assets Historical Data

The historical data trend for Cytophage Technologies's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytophage Technologies Scaled Net Operating Assets Chart

Cytophage Technologies Annual Data

Trend

Dec21

Dec22

Dec23

Scaled Net Operating Assets

0.17

0.23

-0.01

Cytophage Technologies Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Scaled Net Operating Assets	Get a 7-Day Free Trial			-	-	-	-0.01	0.49

Competitive Comparison of Cytophage Technologies's Scaled Net Operating Assets

For the Biotechnology subindustry, Cytophage Technologies's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytophage Technologies's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytophage Technologies's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Cytophage Technologies's Scaled Net Operating Assets falls into.

Cytophage Technologies Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Cytophage Technologies's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2023 )
=	(Operating Assets (A: Dec. 2023 )	-	Operating Liabilities (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2022 )
=	(0.027	-	0.049)	/	3.69
=	-0.01

where

	Operating Assets		(A: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.461	-	5.434
=	0.027

	Operating Liabilities		(A: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	0.049	-	0	-	0
=	0.049

Cytophage Technologies's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2024 )
=	(Operating Assets (Q: Mar. 2024 )	-	Operating Liabilities (Q: Mar. 2024 ))	/	Total Assets (Q: Dec. 2023 )
=	(3.177	-	0.527)	/	5.461
=	0.49

where

	Operating Assets		(Q: Mar. 2024 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	8.745	-	5.568
=	3.177

	Operating Liabilities		(Q: Mar. 2024 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	2.24	-	1.389	-	0.324
=	0.527

Cytophage Technologies Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Cytophage Technologies's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytophage Technologies (TSXV:CYTO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytophage Technologies Ltd (TSXV:CYTO) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Cytophage Technologies Ltd is a Canadian biotechnology company that uses molecular genetic techniques and synthetic biology to create effective bacteriophages to address bacterial challenges affecting animal health, human health, and food security. Bacteriophages are viruses that have evolved to specifically target and destroy strictly bacterial cells and are safe for humans, animals, and plants. To combat dangerous bacteria company generates phages to address specific bacterial infections, including strains resistant to antibiotics. It has also developed a 'phage-display' methodology to develop vaccine-like products using bacteriophages for a number of potential applications in human and animal health.